FDA red and green lights: November 2025
The agency approved eight oncology products over the month.
AnaptysBio and GSK fall out again
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Amgen gets a full approval for Imdelltra
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Zymeworks moves to repeat the Ziihera trick
The company adds royalty aggregation to its R&D business.
